Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
ER Modulation May Overcome AI Resistance in ESR1-Mutant Breast Cancer
December 6th 2019Hope S. Rugo, MD, FASCO, discusses the research being done to develop more effective therapies for patients with advanced hormone receptor–positive, HER2-negative breast cancer who harbor an ESR1 mutation.
Read More
Germline Variants Provide Insight Into Tumor Growth in Prostate Cancer
December 5th 2019Select DNA variants leading to methylation dysregulation within the germline DNA of men with localized prostate cancer were found to be predictive of disease biology, suggesting the prognostic capacity of inherited elements of a patient’s genome, according to data published in Nature Medicine.
Read More
Novel Therapies Surge Forward in Relapsed/Refractory Multiple Myeloma
November 26th 2019Thomas G. Martin, MD, provides insight into novel therapies under evaluation in relapsed/refractory multiple myeloma and the steps that need to be taken prior to and upon the use of these approaches in clinical practice.
Read More
Boosting Impact of Immunotherapy in Earlier NSCLC Settings
November 25th 2019Jamie E. Chaft, MD, explains how the PACIFIC trial has impacted the treatment of patients with stage III unresectable non–small cell lung cancer and the research being done to move immunotherapy into the neoadjuvant setting.
Read More
Immunotherapy Takes Hold in Frontline Advanced Nonsquamous NSCLC
November 18th 2019Jyoti D. Patel, MD, FASCO, discusses the implications of genetic testing, the lasting impact of the KEYNOTE and IMpower trials in patients with advanced nonsquamous non–small cell lung cancer, and considerations for treatment selection.
Read More
Targeted Agents, Immunotherapy Transforming Treatment Across NSCLC Spectrum
November 15th 2019Mark G. Kris, MD, discusses the impact of targeted therapy in patients with EGFR-mutant NSCLC and the encouraging activity that has been reported with checkpoint inhibitors in advanced squamous disease.
Read More
Frontline Immunotherapy Firmly Established for Select Patients With NSCLC
November 11th 2019The use of immunotherapy, either as monotherapy or in combination with chemotherapy, continues to raise the bar with regard to overall survival benefit in patients with newly diagnosed, advanced nonsquamous non–small cell lung cancer.
Read More
Chemoimmunotherapy Transforms Treatment in Nonsquamous NSCLC
November 1st 2019Edward S. Kim, MD, discusses how the use of immunotherapy has resulted in a paradigm shift in advanced nonsquamous non–small cell lung cancer and the steps that are being taken to broaden its use in clinical practice.
Read More
Osimertinib Continues to Flourish as Frontline Standard in EGFR-Mutant NSCLC
October 30th 2019Khaled A. Hassan, MD, MS, discusses the use of EGFR TKIs in the treatment of patients with advanced EGFR-mutant non–small cell lung cancer and the emergence of osimertinib as the frontline standard of care.
Read More